The agreement will allow the implementation of research and training activities, as well as support for PhD students whose doctorates are related to the Chair's area of application
The 14th Workshop on Chagas Disease is focusing on controlling congenital transmission, the mode of transmission that generates the highest number of new acute cases
This is one of the preliminary results of the FLEXO study, presented this weekend as part of the scientific conference on Women's Healthcare at Exeltis Day in Valencia
The Flexo Study assessed the impact of information on contraception in decision-making, with a high level of participation of more than 1,300 women surveyed
More than 300 gynaecologists gathered at the second edition of the Exeltis Day conference to analyse innovative solutions in contraception and the latest developments in Gynaecology
The company will be responsible for distributing, marketing, promoting and producing Bayer's treatment for vaginal infections
The agreement projects a transition period of 2 years, covering countries in Central and South America
Vaginal infections are currently the main cause of visits to gynaecologists. In fact, it is estimated that around 1.5 million suffer from this condition every year in Brazil
The second Exeltis Day scientific conferences are being held today and tomorrow in Valencia, bringing together over 300 gynaecologists to examine the latest developments in gynaecology
This will also be the stage where the preliminary findings of the FLEXO study will be presented, assessing the impact of information about contraception
New technologies and social media in gynaecology will be some of the current issues discussed during these days
8 November 2017 | Geneva −− The World Health Organization (WHO) and the Mundo Sano Foundation are working to make an essential antiparasitic medicine for treatment of Chagas disease widely accessible to children. Treatment with benznidazole in the early stages of infection can cure the Chagas disease, but currently very few people are able to access diagnosis and treatment services.
This investment will help the inventor of the IUB™ intrauterine platform to boost its expansion and increase manufacturing capacity
Chemo Group is already marketing the spherical copper intrauterine device in several European countries
Exeltis Spain, a company that belongs to the Chemo Group, has acquired Juste's Pharma Unit in an operation that includes the sourcing, research, manufacture (through third parties), promotion and sale of pharmaceutical products for Gynaecology, the Central Nervous System and Primary Care, featuring drugs used to treat insomnia, depression and epilepsy. In the words of Exeltis's General Manager in Spain and Portugal, Alberto Fábregas: “The aim of this operation is to strengthen and increase the company's range of products, and to consolidate Exeltis's presence in the Iberian market, by incorporating the expertise and professionals of Juste's Pharma Unit”.